GW Pharmaceuticals Limited Sustainability Profile
GW Pharmaceuticals Limited, a pioneering biopharmaceutical company headquartered in Great Britain, has established itself as a leader in the cannabis-based medicine industry. Founded in 1998, the company has made significant strides in developing innovative therapies derived from cannabis, particularly for neurological conditions. With a strong focus on research and development, GW Pharmaceuticals is renowned for its flagship product, Epidiolex, the first FDA-approved cannabidiol (CBD) medication for epilepsy. This groundbreaking achievement underscores the company's commitment to advancing cannabinoid science and improving patient outcomes. Operating primarily in Europe and North America, GW Pharmaceuticals has garnered a notable market position, recognised for its rigorous clinical trials and regulatory compliance. As the industry evolves, GW continues to set benchmarks in the therapeutic use of cannabis, solidifying its reputation as a trusted name in the biopharmaceutical sector.
DitchCarbon Score
How does GW Pharmaceuticals Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
GW Pharmaceuticals Limited's score of 25 is lower than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
GW Pharmaceuticals Limited, headquartered in Great Britain, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Jazz Pharmaceuticals plc, which may influence its climate commitments and reporting practices. As of now, GW Pharmaceuticals has not established any documented reduction targets or specific climate pledges. The lack of emissions data and reduction initiatives suggests that the company may be in the early stages of developing its climate strategy or may rely on the broader commitments of its parent company, Jazz Pharmaceuticals plc. Given the context of the pharmaceutical industry, it is essential for companies like GW Pharmaceuticals to align with industry standards and best practices in climate action. This includes potentially adopting science-based targets and engaging in initiatives that promote sustainability and carbon footprint reduction. In summary, while GW Pharmaceuticals Limited does not currently provide specific emissions data or reduction targets, its affiliation with Jazz Pharmaceuticals plc may play a role in shaping its future climate commitments.
How Carbon Intensive is GW Pharmaceuticals Limited's Industry?
How Carbon Intensive is GW Pharmaceuticals Limited's Location?
GW Pharmaceuticals Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
GW Pharmaceuticals Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
